Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

63.43 USD +0.24 (+0.38%)
Streaming Delayed Price Updated: 2:50 PM EDT, Oct 1, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,600,014
Open 63.33
Bid (Size) 63.42 (3)
Ask (Size) 63.43 (6)
Prev. Close 63.19
Today's Range 62.71 - 63.69
52wk Range 60.89 - 85.97
Shares Outstanding 1,300,260,832
Dividend Yield 3.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Gilead Sciences Update on Supply and Distribution of Veklury® (remdesivir) in the United States
Since the COVID-19 pandemic began, Gilead has worked diligently to ramp up production and rapidly expand the supply of our investigational antiviral drug Veklury® (remdesivir) by making significant... 
From Business Wire News Releases
Gilead Sciences Presents Data From HIV Research and Development Programs at HIV Glasgow 2020
Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the HIV Glasgow 2020 conference, taking place virtually from October 5-8. Gilead will present 13 studies from the... 
From Business Wire News Releases

Performance

YTD
-2.76%
-2.76%
1 Month
-4.97%
-4.97%
3 Month
-16.61%
-16.61%
6 Month
-12.52%
-12.52%
1 Year
+0.33%
+0.33%

More News

Read More
Unprecedented Global Turmoil Underlines Need for Effective Diagnostics
From PR Newswire
Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis
From ACN Newswire
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
From Business Wire News Releases
EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ACTIVE RHEUMATHOID ARTHRITIS
From GlobeNewswire News Releases
Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis
From Business Wire News Releases
Jyseleca® (filgotinib) approved in Japan for rheumatoid arthritis
From GlobeNewswire News Releases
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes
From Business Wire News Releases
Investors Are Scrambling To Get Ahead Of The Oncology Drug Market Boom; 1 Company Could Revolutionize The Industry
From Penny Stocks to Buy, Picks, News and Information | PennyStocks.com - Feed
Unusual Options Activity Insight: Gilead Sciences
Tags Markets GILD Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]